...
首页> 外文期刊>Journal of Medicinal Chemistry >Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists
【24h】

Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists

机译:在2-氨基双苯基亚基上的卤素引入卤素,导致高效和选择性的M3毒蕈碱乙酰胆碱受体拮抗剂和弱逆激动剂

获取原文
获取原文并翻译 | 示例

摘要

Muscarinic M-3 receptor antagonists and inverse agonists displaying high affinity and subtype selectivity over the antitarget M-2 are valuable pharmacological tools and may enable improved treatment of chronic obstructive pulmonary disease (COPD), asthma, or urinary incontinence. On the basis of known M-3 antagonists comprising a piperidine or quinuclidine unit attached to a biphenyl carbamate, S-fluoro substitution was responsible for M-3 subtype selectivity over M-2, while 3'-chloro substitution substantially increased affinity through a sigma-hole interaction. Resultantly, two piperidinyl- and two quinuclidinium-substituted biphenyl carbamates OFH243 (13n), OFH244 (13m), OFH3911 (14n), and OFH3912 (14m) were discovered, which display two-digit picomolar affinities with K-i values from 0.069 to 0.084 nM, as well as high selectivity over the M-2 subtype (46- to 68-fold). While weak inverse agonistic properties were determined for the biphenyl carbamates 13m and 13n, neutral antagonism was observed for 14m and 14n and tiotropium under identical assay conditions.
机译:肌肉蛋白M-3受体拮抗剂和逆激动剂在抗真菌M-2上显示高亲和力和亚型选择性是有价值的药理学工具,并且可以改善慢性阻塞性肺病(COPD),哮喘或尿失禁的治疗。在已知的M-3拮抗剂的基础上,所述哌啶或附着在联苯氨基甲酸甲酸氨基甲酸氨基甲酸氨基甲酸氨基甲酸氨基甲酸酯的基础上,S-Fluoro取代对M-3的M-3亚型选择性负责,而3'-氯取代通过Sigma基本上增加了亲和力 - 孤立。结果,发现,发现了两种哌啶基 - 和两种哌啶基 - 和两种氨基氯丙基丙烯酸二苯基氨基氨基氨基酯,OH 3911(13M),OFH3911(14N)和H3912(14M),其显示两位数的皮摩尔亲显性,Ki值从0.069〜0.084nm以及对M-2亚型的高选择性(46-至68倍)。虽然针对联苯氨基氨基酯13M和13N测定弱反向激动性质,但在相同的测定条件下观察到14M和14N和噻托溴铵的中性拮抗作用。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2020年第8期| 共21页
  • 作者单位

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Inst Expt &

    Clin Pharmacol &

    Toxicol D-91054 Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Inst Expt &

    Clin Pharmacol &

    Toxicol D-91054 Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

    Friedrich Alexander Univ Erlangen Nurnberg Dept Chem &

    Pharm Pharmaceut Chem Erlangen Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号